Figure][1] Michael Teitell, MD, PhD Dr. Michael Teitell is the director of the UCLA Health Jonsson Comprehensive Cancer ...

Radiopharmaceutical therapy (RPT) offers molecular-targeted treatment strategies and presents an ideal model for advancing ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.

Journal of Nuclear Medicine December 2025, jnumed.125.271365; DOI: https://doi.org/10.2967/jnumed.125.271365 ...

Irène Buvat, PhD, Centre National de la Recherche Scientifique director of research and head of the Inserm Laboratory of Translational Imaging in Oncology at the Institut Curie, Orsay (France), and ...

Journal of Nuclear Medicine December 2025, jnumed.125.270792; DOI: https://doi.org/10.2967/jnumed.125.270792 ...

TO THE EDITOR: In the article written by Veit-Haibach et al. (1), the authors highlight the growing interest in the use of radiopharmaceuticals for both diagnosis and treatment, with a significant ...

The subjects of this study were those who underwent conventional wbPET imaging for clinical examination, for free medical treatment, or as part of the Japan Agency for Medical Research and Development ...

Thyroid nodules (TN) are commonly encountered in clinical practice, with a prevalence ranging between 20% and 60% in prospective, randomly selected patients (1–3). Although some may cause local ...

Identifying cancer therapy resistance is a key time-saving tool for physicians. Part of chemotherapy resistance includes senescence, a persistent state without cell division or cell death. Chemically ...

In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their ...

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case ...